CELC — Celcuity Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1603454 ·
Last close
$88.05
Market Cap
$4.29B
52W High
$151.02
52W Low
$83.77
ADV30
1,575,235
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -50,507,000 | -52,841,000 | 410,164,000 | 145,191,000 | 356,639,000 |
| Dec 2025 | 0 | — | -49,201,000 | -50,973,000 | 466,558,000 | 165,703,000 | 366,003,000 |
| Sep 2025 | 0 | — | -42,849,000 | -43,804,000 | 476,004,000 | 74,252,000 | 359,041,000 |
| Jun 2025 | 0 | — | -44,009,000 | -45,268,000 | 183,592,000 | 46,354,000 | 139,217,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,492,000
Investing CF
$-53,827,000
Financing CF
$355,032,000
CapEx
$-474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.90
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,738,000
Inventory
—
Receivables
$1,600,621
ST Investments
$241,873,000
EBIT TTM
$-172,836,000
Pretax Income TTM
$-192,886,000
Interest Exp TTM
$20,050,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,192,000 | -177,042,000 | 466,558,000 | 366,003,000 | — | -153,280,000 |
| Dec 2024 | 0 | -113,267,000 | -111,779,000 | 245,123,000 | 129,504,000 | — | -83,467,000 |
| Dec 2023 | 0 | -66,230,331 | -63,779,116 | 191,219,398 | 51,450,076 | — | -53,812,253 |
| Dec 2022 | 0 | -39,391,091 | -40,370,040 | 175,697,097 | 41,925,630 | — | -36,008,171 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.74
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $100.00 · spot: $88.05 · call volume: 739 · put volume: 735
Expected Move to 2026-07-17:
±$14.30
(16.24%) —
implied range
$73.75 –
$102.35
· ATM straddle on $90.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SHC | Sotera Health Co | $4.41B | $15.46 | — |
| RDNT | RadNet, Inc. | $4.15B | $52.82 | — |
| BLLN | BillionToOne, Inc. | $4.12B | $99.38 | — |
| VCYT | VERACYTE, INC. | $4.09B | $51.29 | — |
| CAI | Caris Life Sciences, Inc. | $5.05B | $17.86 | — |
News headlines (Yahoo Finance, 1h cache)
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering
2026-06-04 19:11 · Yahoo
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
2026-06-04 09:07 · Yahoo
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
2026-06-04 02:13 · Yahoo
US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East
2026-06-03 13:04 · Yahoo
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
2026-06-03 11:19 · Yahoo
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?
2026-06-02 20:56 · Yahoo
Celcuity Crashes On Breast Cancer Disappointment. What Happened?
2026-06-02 20:28 · Yahoo
Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial
2026-06-02 19:09 · Yahoo
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
2026-06-02 15:52 · Yahoo
Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)
2026-06-02 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.